Oncurious has licensed five immuno-oncology candidates developed at VIB to expand its pipeline of cancer therapies.
The young Belgian biotech Oncurious has decided to step up its game through an agreement with the Vlaams Institute for Biotechnology (VIB) in Flanders that gives it exclusive licenses to five next-generation immunotherapy candidates. In exchange, the VIB is increasing its shares in the company and will receive royalties on future sales of the drugs. ThromboGenics, the main shareholder, will chip in with an additional €2.1M.
The new candidates will be an addition to Oncurious’ lead program, TB-403, currently in Phase I/IIa trials for medulloblastoma, a form of brain cancer that accounts for 20% of brain tumors in children. The experimental therapy consists of a monoclonal antibody against placental growth factor (PlGF) with potential to become the first targeted therapy to treat medulloblastoma.
Image via Bika Ambon / Shutterstock